Suchergebnisse - "Avorn, Jerry"

PubPharm (915)

1

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies

enthalten in: JAMA oncology | 2024

von Tibau, A. | Hwang, T. | Molto, C. | +2

2

Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis

enthalten in: JAMA dermatology | 2024

von Egilman, A. | Kesselheim, A. | Avorn, J. | +2

CommentOn: JAMA Dermatol. 2024 Apr 1;160(4):387-388. - PMID 38381443

3

Pragmatic trial evaluating the impact of simulation training on high-risk prescribing to older adults by junior physicians

enthalten in: Journal of the American Geriatrics Society | 2024

von Lauffenburger, J. | DiFrancesco, M. | Bhatkhande, G. | +9

4

Patient Characteristics Associated With Using Transcatheter Left Atrial Appendage Occlusion Versus Oral Anticoagulants for Atrial Fibrillation

enthalten in: Circulation. Cardiovascular quality and outcomes | 2024

von Lin, K. | Singer, D. | Avorn, J. | +6

5

Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease

enthalten in: Annals of internal medicine | 2024

von Feldman, W. | Kesselheim, A. | Avorn, J. | +2

CommentOn: Ann Intern Med. 2024 Jan;177(1):eL230428. - PMID 38224597

6

Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine Care

enthalten in: JAMA network open | 2024

von Hong, D. | Avorn, J. | Wyss, R. | +1

7

Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

enthalten in: JAMA neurology | 2024

von Kim, J. | Kesselheim, A. | Bove, R. | +2

8

Wedding Websites, Free Speech, and Adverse Drug Effects

enthalten in: The New England journal of medicine | 2023

von Avorn, J.

9

The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence

enthalten in: Annals of internal medicine | 2023

von Bendicksen, L. | Zuckerman, D. | Avorn, J. | +2

10

Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease

enthalten in: Annals of internal medicine | 2023

von Feldman, W. | Kesselheim, A. | Avorn, J. | +2

CommentIn: Ann Intern Med. 2024 Jan;177(1):eL230428. - PMID 38224597

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[92]